

Daiichi Sankyo unveils APAC regional hub for RDPV QA operations in Singapore

22 February 2024 | Company results

The new Singapore subsidiary features exclusive RDPV QA (Research & Development, Pharmacovigilance, and Quality Assurance) functions to focus on Antibody-Drug Conjugates for Cancer



Daiichi Sankyo, an innovative global healthcare company, has launched its subsidiary Daiichi Sankyo Singapore Pte. Ltd. to bridge unmet needs in oncology.

The Singapore subsidiary will be home to the **RDPV QA (Research & Development, Pharmacovigilance, and Quality Assurance) function**. This new Asia Pacific regional hub will be a centre of excellence, ensuring the highest Quality standards in Research & Development, Pharmacovigilance, Medical Affairs and key processes and systems across the region.

Daiichi Sankyo Singapore will focus on antibody-drug conjugates (ADCs), a class of drugs that offer targeted precision and potent drug delivery to certain tumour types. ADCs deliver potent cancer-killing agents directly to cancer cells to eliminate them, whilst limiting damage to healthy surrounding cells.

Daiichi Sankyo's portfolio currently consists of six DXd ADCs in clinical development across multiple types of cancer, with one of them now in commercialisation.

"Daiichi Sankyo's decision to set up in Singapore reflects our strength as a global biomedical sciences hub and will further enrich our ecosystem with capabilities in precision therapeutics. We look forward to seeing Daiichi Sankyo's growth and efforts to bring forth novel drugs that would benefit patients around the world," said Ms Goh Wan Yee, Senior Vice President and Head, Healthcare Division, Singapore Economic Development Board.

"Singapore has increasingly been becoming an important global hub for precision cancer treatment research and innovation. Therefore, with our proprietary DXd ADC technology, we are excited to contribute to improving outcomes for people living

with cancer in Singapore,” said Koichi Morino, Managing Director of Daiichi Sankyo Singapore.

The launch is strengthening Daiichi Sankyo's commitment to creating new employment and treatment opportunities in Singapore, while bringing forward new methods of drug delivery to the oncology market.

As part of the Daiichi Sankyo Quality Assurance organisation, the newly set up RDPV QA (Research & Development, Pharmacovigilance, and Quality Assurance) function in Singapore signifies a strategic leap forward in reinforcing patient safety with rigorous quality assurance.

Image Caption: (L-R) Dr Ken Takeshita, Global Head, Research & Development, Daiichi Sankyo; Mr Hiroyuki Okuzawa, Representative Director, President & Chief Operating Officer, Daiichi Sankyo; His Excellency, Hiroshi Ishikawa, Ambassador of Japan to Singapore; Mr Tan Kong Hwee, Executive Vice President and EXCO Member, Singapore Economic Development Board; Mr Koichi Morino, Managing Director, Daiichi Sankyo Singapore at the launch of Daiichi Sankyo Singapore